SPX-608

SPX-608 is a preclinical-stage antibody-drug conjugate (ADC) being developed by SparX Biopharmaceutical for the treatment of cancer. It is built upon the company's proprietary Nab2 dual-payload platform, which is designed to deliver two distinct cytotoxic agents to the target site simultaneously. This dual-payload approach aims to enhance anti-tumor efficacy and potentially overcome drug resistance mechanisms that often limit the effectiveness of single-payload ADCs. While the specific molecular target for SPX-608 is broadly categorized as 'immune-targeting,' the drug is intended to selectively bind to antigens on tumor or immune cells to deliver its therapeutic payloads. As of early 2024, SPX-608 remains in the preclinical development phase and is listed as open for collaboration.